全文获取类型
收费全文 | 2577085篇 |
免费 | 189420篇 |
国内免费 | 7552篇 |
专业分类
耳鼻咽喉 | 34273篇 |
儿科学 | 85121篇 |
妇产科学 | 71575篇 |
基础医学 | 362838篇 |
口腔科学 | 69679篇 |
临床医学 | 233496篇 |
内科学 | 513215篇 |
皮肤病学 | 62464篇 |
神经病学 | 213042篇 |
特种医学 | 99940篇 |
外国民族医学 | 736篇 |
外科学 | 386378篇 |
综合类 | 50259篇 |
现状与发展 | 5篇 |
一般理论 | 967篇 |
预防医学 | 194966篇 |
眼科学 | 56692篇 |
药学 | 188024篇 |
8篇 | |
中国医学 | 5269篇 |
肿瘤学 | 145110篇 |
出版年
2021年 | 19475篇 |
2019年 | 20700篇 |
2018年 | 29360篇 |
2017年 | 22669篇 |
2016年 | 26309篇 |
2015年 | 29600篇 |
2014年 | 40572篇 |
2013年 | 60569篇 |
2012年 | 80479篇 |
2011年 | 84769篇 |
2010年 | 51151篇 |
2009年 | 49278篇 |
2008年 | 79254篇 |
2007年 | 84131篇 |
2006年 | 85803篇 |
2005年 | 81983篇 |
2004年 | 78959篇 |
2003年 | 76246篇 |
2002年 | 73533篇 |
2001年 | 128502篇 |
2000年 | 131410篇 |
1999年 | 110586篇 |
1998年 | 31303篇 |
1997年 | 27854篇 |
1996年 | 26458篇 |
1995年 | 27257篇 |
1994年 | 24972篇 |
1993年 | 23311篇 |
1992年 | 85119篇 |
1991年 | 81596篇 |
1990年 | 78781篇 |
1989年 | 76049篇 |
1988年 | 69444篇 |
1987年 | 67993篇 |
1986年 | 63543篇 |
1985年 | 60508篇 |
1984年 | 44908篇 |
1983年 | 37875篇 |
1982年 | 22381篇 |
1981年 | 19917篇 |
1979年 | 38909篇 |
1978年 | 27382篇 |
1977年 | 23194篇 |
1976年 | 21429篇 |
1975年 | 22769篇 |
1974年 | 26751篇 |
1973年 | 25349篇 |
1972年 | 23748篇 |
1971年 | 21952篇 |
1970年 | 20174篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
51.
52.
53.
Robert C. Lynall J. Troy Blackburn Kevin M. Guskiewicz Stephen W. Marshall Prudence Plummer Jason P. Mihalik 《Journal of Science and Medicine in Sport》2019,22(5):503-508
Objectives
Despite evidence for increased musculoskeletal injury after concussion recovery, there is a lack of dynamic balance assessments that could inform management and research into this increased injury risk post-concussion. Our purpose was to identify tandem gait dynamic balance deficits in recreational athletes with a concussion history within the past 18-months compared to matched controls.Design
Cross-sectional, laboratory study.Methods
Fifteen participants with a concussion history (age: 19.7 ± 0.9 years; 9 females; median time since concussion 126 days, range 28–432 days), and 15 matched controls (19.7 ± 1.6 years; 9 females) with no recent concussion history participated. We measured center-of-pressure (COP) outcomes (velocity, path length, speed, dual-task cost) under 4 tandem gait conditions: (1) tandem gait, (2) tandem gait, eyes closed, (3) tandem gait, eyes open, cognitive distraction, and (4) tandem gait, eyes closed, cognitive distraction.Results
The concussion history group demonstrated slower tandem gait velocity compared to the control group (4.0 cm/s difference), thus velocity was used as a covariate when analyzing COP path length and speed. The concussion history group (23.5%) demonstrated greater COP speed dual-task cost than the control group (16.3%) during the eyes closed dual-task condition. No other comparisons were statistically significant.Conclusions
There may be subtle dynamic balance differences during tandem gait that are detectable after return-to-activity following concussion, but the clinical significance of these findings is unclear. Longitudinal investigations should identify acute movement deficits in varying visual and cognitive scenarios after concussion in comparison with recovery on traditional concussion assessment tools while also recording musculoskeletal injury outcomes. 相似文献54.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
55.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
56.
Key Jana Maletzko Antonia Kohli Aneesha Gispert Suzana Torres-Odio Sylvia Wittig Ilka Heidler Juliana Bárcena Clea López-Otín Carlos Lei Yuanjiu West A. Phillip Münch Christian Auburger Georg 《Neurogenetics》2020,21(3):187-203
neurogenetics - Human RNF213, which encodes the protein mysterin, is a known susceptibility gene for moyamoya disease (MMD), a cerebrovascular condition with occlusive lesions and compensatory... 相似文献
57.
58.
59.
Stepanova E. S. Makarenkova L. M. Chistyakov V. V. Rybakov Yu. L. Gukasov V. M. Fedotcheva T. A. Parshin V. A. Votyakov V. A. Shimanovskii N. L. 《Pharmaceutical Chemistry Journal》2019,52(12):1016-1020
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was... 相似文献
60.
M.F. Werner A. López-Rueda F.X. Zarco J. Blasco L. San Román S. Amaro E. Carrero R. Valero L. Oleaga J.M. Macho N. Bargalló 《Radiologia》2019,61(2):143-152